Phathom Pharmaceuticals (PHAT) PT Raised to $12 at Goldman Sachs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. TMUS
9. SPY
10. SBUX

Go back to Phathom Pharmaceuticals (PHAT) PT Raised to $12 at Goldman Sachs

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

August 8, 2024 8:00 AM EDT

Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly report
Net revenues of $7.3 million reported for the second quarter 2024 compared to $1.9 million in the first quarter 2024, greater than a 280% increase
VOQUEZNA (vonoprazan) tablets 10mg now FDA-approved and available to treat heartburn associated with Non-Erosive Gastroesophageal Reflux Disease (GERD) in adults unlocking the entire GERD market of over 22 million diagnosed and annually treated patients
Expansion of commercial coverage for VOQUEZNA tablets now includes over 116 million U.S. lives, an estimated 77% of total... More